Related Experiment Videos
Long-term use of sildenafil
1University of North Carolina School of Medicine, Chapel Hill 27599-7000, USA. carson@med.unc.edu
Expert Opinion on Pharmacotherapy
|March 5, 2003
Summary
Selective PDE5 inhibition, like with sildenafil, effectively treats erectile dysfunction (ED) by relaxing smooth muscle. This approach is safe and works for all causes and severities of ED.
Area of Science:
- Pharmacology
- Urology
- Molecular Biology
Background:
- Erectile dysfunction (ED) treatment has advanced with phosphodiesterase type 5 (PDE5) inhibitors.
- PDE5 inhibition facilitates corpus cavernosum smooth muscle relaxation via cyclic guanosine monophosphate (cGMP) pathway.
Purpose of the Study:
- To review the clinical efficacy and safety of sildenafil, a selective PDE5 inhibitor, for treating ED.
- To evaluate the mechanism of action and adverse effects associated with PDE5 inhibition in ED management.
Main Methods:
- Review of pre- and post-marketing clinical studies on sildenafil.
- Analysis of PDE5 inhibition's biochemical pathway and selectivity over other phosphodiesterases (e.g., PDE6).
Main Results:
- Sildenafil demonstrates significant clinical effectiveness in men with ED across various etiologies.
- PDE5 inhibition by sildenafil is highly selective, with minimal activity against PDE6, reducing visual side effects.
- Adverse events like headache and flushing are typically mild and decrease with continued use.
Conclusions:
- Selective PDE5 inhibition is a clinically validated, safe, and effective treatment for ED.
- Sildenafil's mechanism of action is consistent across different causes and severities of erectile dysfunction.
- PDE5 inhibitors represent a cornerstone therapy for managing erectile dysfunction.